X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nyxol (phentolamine mesylate ophthalmic solution) an alpha1/2 adrenergic receptor inhibitor, is being investigated in a phase 3 trial for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
Nyxol (phentolamine ophthalmic solution) is anadrenergic receptor antagonist. It is being evaluated in phase 3 clinical trials for the treatment of decreased visual acuity under dim (mesopic) light conditions.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
Ryzumvi (phentolamine ophthalmic solution) 0.75% is a preservative-free ophthalmic solution and a nonselective alpha adrenergic antagonist, which is investigated for Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Ryzumvi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
APX3330 is a first-in-class, small molecule, oral inhibitor of transcription factor regulator Ref-1, including those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease their abnormal activation that are implicated across several ocular diseases.
Lead Product(s): APX3330
Therapeutic Area: Ophthalmology Product Name: APX3330
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris.
Lead Product(s): Phentolamine Mesylate,Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Nyxol is a proprietary, preservative-free, stable, investigational eye drop formulation of phentolamine mesylate 0.75% designed to uniquely modulate the pupil size by blocking the α1 receptors found only on the iris dilator muscle without affecting the ciliary muscle.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
Under the terms of the license agreement, Famy will fund Nyxol (phentolamine mesylate) development through FDA approvals, that will be managed by Ocuphire, including clinical, manufacturing, and regulatory activities required for FDA approval of all three Nyxol indications.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: FamyGen Life Sciences
Deal Size: $45.0 million Upfront Cash: $35.0 million
Deal Type: Licensing Agreement November 07, 2022
Details:
Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Nyxol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: American Society of Ophthalmic Administrator
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 02, 2022
Details:
APX3330, a novel, first-in-class, twice-daily oral tablet drug candidate, specifically targets Apurinic/Apyrimidinic Endonuclease 1/Redox Effector Factor-1 (APE1/Ref-1) protein, referred to as Ref-1.
Lead Product(s): APX3330
Therapeutic Area: Ophthalmology Product Name: APX3330
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
